Home›Trial›NCT07230860
🔬NCT07230860Phase 2RECRUITING

A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

Study Summary

The purpose of this study is to assess how well JNJ-95597528 works compared to placebo in participants with moderate to severe atopic dermatitis (AD).

Conditions
Dermatitis, Atopic
Interventions / Drugs
JNJ-95597528Placebo
View on ClinicalTrials.gov ↗
Sponsor
JNJ
Johnson & Johnson
Diversified Pharma
C60/100
Study Details
Enrollment180 participants
Primary Completion—
Lead SponsorJanssen Research & Development, LLC
Data Retrieved2026-04-11 02:55:31.550102+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.